Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation and dose-expansion study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

The study examined the immunotherapy agent in a variety of solid tumors, Rafii says. In the urothelial bladder cancer cohort, the overall response rate was 25% in patients with liver metastases and 50% in patients with lymph node‒only disease. Response rates to chemotherapy for patients with this disease, he adds, have generally been low.

Additionally, responses are ongoing in 15 out of 16 patients enrolled in this study. The longest duration of response is ongoing at 11.3 months.